Vyluma Entered into an Exclusive License Agreement with Théa for the Registration and Commercialization of NVK002 to Treat Myopia
Shots:
- Vyluma is eligible to receive ~$150M upon achievement of regulatory & sales milestones across the Théa-licensed markets in the EU, Canada & Latin America along with royalty on net sales of NVK002 under the expanded agreement
- The companies expand its 2021 license agreement for the commercialization of NVK002 in the EU & other select countries. Vyluma has a strong pipeline of additional assets in multiple stages of development that address unmet treatment needs of patients with refractive errors or eye pain
- NVK002 is a preservative-free eye drop that is used nightly to slow the progression of myopia in children aged 3 to 17yrs. & is currently under late-stage clinical evaluation in the P-III (CHAMP) study across the US & EU
Ref: GlobalNewswire | Image: Vyluma
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
